Next Article in Journal
The Impact of Cellular Proliferation on the HIV-1 Reservoir
Next Article in Special Issue
Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines
Previous Article in Journal
Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice
Previous Article in Special Issue
Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation
Open AccessReview

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, Victoria 3000, Australia
Royal Melbourne Institute of Technology (RMIT) University, School of Science, Melbourne, Victoria 3001, Australia
Author to whom correspondence should be addressed.
Viruses 2020, 12(2), 126;
Received: 19 December 2019 / Revised: 13 January 2020 / Accepted: 13 January 2020 / Published: 21 January 2020
(This article belongs to the Special Issue Virus-Like Particle Vaccines)
Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point in combating this virus was the development of a preventative vaccine composed of the HBV surface (envelope) protein (HBsAg) to reduce the risk of new infections. The isolation of HBsAg sub-viral particles (SVPs) from the blood of asymptomatic HBV carriers as antigens for the first-generation vaccines, followed by the development of recombinant HBsAg SVPs produced in yeast as the antigenic components of the second-generation vaccines, represent landmark advancements in biotechnology and medicine. The ability of the HBsAg SVPs to accept and present foreign antigenic sequences provides the basis of a chimeric particulate delivery platform, and resulted in the development of a vaccine against malaria (RTS,S/AS01, MosquirixTM), and various preclinical vaccine candidates to overcome infectious diseases for which there are no effective vaccines. Biomedical modifications of the HBsAg subunits allowed the identification of strategies to enhance the HBsAg SVP immunogenicity to build potent vaccines for preventative and possibly therapeutic applications. The review provides an overview of the formation and assembly of the HBsAg SVPs and highlights the utilization of the particles in key effective vaccines. View Full-Text
Keywords: hepatitis B virus; surface (envelope) antigen; sub-viral particle; virus-like particle hepatitis B virus; surface (envelope) antigen; sub-viral particle; virus-like particle
Show Figures

Figure 1

MDPI and ACS Style

Ho, J. .-T.; Jeevan-Raj, B.; Netter, H.-J. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses 2020, 12, 126.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop